Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the blood and bone marrow that develops from a specific type of white blood cell called a B lymphocyte. It is the most common leukemia in adults, with a five-year relative survival rate of about 90%. Unlike many cancers that form tumors in a single location, CLL causes abnormal lymphocytes to accumulate in the blood, bone marrow, and lymph nodes over time, gradually crowding out healthy blood cells.
How CLL Develops
Your immune system relies on B lymphocytes to produce antibodies and fight infection. In CLL, a single B cell acquires genetic changes that cause it to multiply uncontrollably. These cancerous cells look like normal resting lymphocytes under a microscope, but they don’t function properly and they don’t die on schedule the way healthy cells do.
The accumulation is surprisingly dynamic. Even in patients whose disease appears stable, between 0.1% and 1% of the entire leukemia cell population is replaced each day. That high turnover is balanced by an equally high rate of cell death, which is why CLL can remain quiet for years. When the balance tips toward growth, the disease progresses: lymph nodes enlarge, the spleen swells, and the bone marrow becomes so packed with leukemia cells that it can no longer produce enough red blood cells or platelets.
CLL vs. Small Lymphocytic Lymphoma
You may come across the term small lymphocytic lymphoma (SLL). CLL and SLL are considered the same disease. The distinction is simply where the cancer shows up most. If abnormal B cells are primarily circulating in the blood, it’s called CLL. If they’re concentrated in the lymph nodes and organs without a significant rise in blood lymphocyte counts, it’s classified as SLL. Treatment and prognosis are essentially the same for both.
Symptoms and Early Signs
Most people with CLL have no symptoms at diagnosis. The cancer is often discovered incidentally when routine blood work shows an unexpectedly high white blood cell count. This is one reason the disease can go undetected for years.
When symptoms do appear, they tend to develop gradually. Swollen lymph nodes in the neck, armpits, or groin are common. You might notice fatigue that doesn’t improve with rest, a feeling of fullness or discomfort in the upper left abdomen (from an enlarged spleen), or frequent infections. Only about 5 to 10% of CLL patients have what oncologists call “B symptoms” at the time of diagnosis:
- Fever above 100.5°F lasting more than two weeks without an infection
- Drenching night sweats persisting for a month or longer
- Unintentional weight loss of 10% or more of body weight within six months
- Extreme fatigue that interferes with daily activities
- Early satiety, or feeling full after eating very little
These symptoms signal more active disease and typically factor into decisions about when to start treatment.
How CLL Is Diagnosed
A CLL diagnosis requires a blood test showing at least 5,000 monoclonal (genetically identical) B lymphocytes per microliter of blood. A technique called flow cytometry confirms the diagnosis by identifying specific protein markers on the surface of those cells. CLL cells carry a distinctive combination of markers, most notably CD5 and CD23, that distinguish them from other types of lymphoma or leukemia.
A bone marrow biopsy is not always needed for diagnosis but may be performed later to assess how much the marrow is affected, particularly before starting treatment.
Staging: How Far the Disease Has Spread
Two staging systems are used depending on where you’re being treated. In the United States, the Rai system is more common. In Europe, the Binet system is standard. Both are based on physical exam findings and blood counts rather than imaging scans.
The Rai system starts at stage 0, where the only finding is a high lymphocyte count, and progresses through stages I to IV based on the sequential appearance of enlarged lymph nodes, an enlarged spleen or liver, anemia, and low platelet counts. The underlying concept is that CLL follows a predictable pattern: it begins in the blood and marrow, spreads to lymph nodes and organs, and eventually impairs the bone marrow’s ability to produce normal blood cells.
The Binet system takes a simpler approach, dividing patients into three groups. Stage A means fewer than three areas of enlarged lymph nodes or organs. Stage B means three or more areas are involved. Stage C means anemia or low platelets have developed, regardless of how many lymph node areas are affected. Stage C in either system signals advanced disease that typically requires treatment.
Genetic Changes That Shape Prognosis
Not all CLL behaves the same way. Genetic testing on the leukemia cells themselves is one of the most important tools for predicting how the disease will progress and which treatments will work.
The most common chromosomal change is a deletion on chromosome 13, found in more than half of all CLL patients. When this is the only abnormality, it’s associated with a favorable prognosis and slow disease progression. At the other end of the spectrum, a deletion on chromosome 17 (called 17p deletion) or mutations in the TP53 gene place patients in the highest risk category. These patients have shorter survival times and don’t respond to traditional chemotherapy regimens.
A deletion on chromosome 11 falls between these extremes. It’s associated with bulky lymph node enlargement, faster disease progression, and shorter remissions after standard chemotherapy. Having three or more chromosomal abnormalities at once, known as a complex karyotype, also predicts a more aggressive course and is often seen alongside 11q or 17p deletions.
These genetic results directly influence treatment choices, which is why most specialists order this testing before recommending therapy.
Watch and Wait
One of the most surprising aspects of CLL for newly diagnosed patients is that many don’t need treatment right away. If you have early-stage disease without symptoms, your doctor will likely recommend active surveillance, sometimes called “watch and wait.” This means regular blood tests and checkups, typically every few months, without any medication.
This isn’t neglect. Multiple studies have shown that treating early-stage, asymptomatic CLL does not improve survival compared to waiting until the disease progresses. Treatment begins when specific criteria are met, as defined by international CLL guidelines. Triggers include rapidly rising lymphocyte counts, progressive lymph node enlargement, worsening anemia or platelet counts, significant B symptoms, or a spleen that is growing and causing discomfort.
Some patients remain on watch and wait for years, even decades. Others progress within months. The genetic profile of the leukemia cells is one of the strongest predictors of how quickly that transition happens.
Treatment Options
CLL treatment has changed dramatically in the past decade. Traditional chemotherapy combinations have been largely replaced by targeted therapies that block specific proteins the cancer cells need to survive.
The most widely used class of drugs are BTK inhibitors, which block a signaling protein that CLL cells depend on to grow and stay alive. Ibrutinib was the first to be approved and transformed CLL care. Newer versions like acalabrutinib and zanubrutinib were designed to be more selective, reducing some of the side effects seen with ibrutinib while maintaining effectiveness. These drugs are taken as daily pills, often indefinitely, and most patients see their lymph node swelling and blood counts improve within weeks to months.
Another major option targets a protein called BCL-2 that prevents cancer cells from undergoing their normal programmed death. By blocking this protein, the drug forces CLL cells to die. This approach is often given for a fixed duration, typically one to two years, which appeals to patients who prefer not to take medication indefinitely.
For patients with high-risk genetic changes like 17p deletion, these targeted drugs are especially important because standard chemotherapy is ineffective. Newer agents, including a class of reversible BTK inhibitors like pirtobrutinib, offer additional options for patients whose disease stops responding to first-line targeted therapy.
Richter Transformation
In roughly 2 to 10% of people with CLL, the disease transforms into a fast-growing, aggressive lymphoma. This is called Richter transformation, and it represents one of the most serious complications of CLL.
The shift tends to happen suddenly. Symptoms that were previously mild or stable escalate rapidly: lymph nodes swell noticeably, fevers spike, night sweats worsen, weight drops quickly, and fatigue deepens. If you’ve been living with CLL and notice a sudden, marked worsening of symptoms, this possibility is one reason to contact your care team promptly. Richter transformation requires a different, more intensive treatment approach than standard CLL.
Long-Term Outlook
The overall five-year relative survival rate for CLL is 90.2%, based on data from the National Cancer Institute’s SEER program covering 2016 through 2022. That number reflects the impact of modern targeted therapies, which have significantly improved outcomes compared to the chemotherapy era. Individual prognosis varies widely depending on disease stage, genetic features, and how the cancer responds to treatment. Some people with low-risk genetics and early-stage disease have a near-normal life expectancy, while those with high-risk genetic changes face a more challenging course, though even their outcomes have improved substantially with current therapies.